Takeover bids offering a 245% premium over Sorrento Therapeutics's (NASDAQ: SRNE) $1.45 share price last month might seem like a seize-the-day sort of moment. Especially considering Sorrento's financial situation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,